share_log

Dyne Therapeutics Announces Initiation Of Phase 1/2 ACHIEVE Clinical Trial Of DYNE-101 For The Treatment of Myotonic Dystrophy Type 1

Dyne Therapeutics Announces Initiation Of Phase 1/2 ACHIEVE Clinical Trial Of DYNE-101 For The Treatment of Myotonic Dystrophy Type 1

戴恩治療公司宣佈啟動用於治療1型強直性肌營養不良症的戴恩-101的1/2期實現臨牀試驗
Benzinga Real-time News ·  2022/09/06 07:04

Dyne Therapeutics Announces Initiation Of Phase 1/2 ACHIEVE Clinical Trial Of DYNE-101 For The Treatment of Myotonic Dystrophy Type 1

戴恩治療公司宣佈啟動用於治療1型強直性肌營養不良症的戴恩-101的1/2期實現臨牀試驗

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論